Asthma clinical trials are increasingly stratified by phenotype — Type 2 high (eosinophilic, IgE-mediated) versus Type 2 low (neutrophilic or paucigranulocytic) — because this distinction predicts response to biologic therapies. The anti-IL-5, anti-IL-4/13, and anti-TSLP antibody classes have revolutionized severe asthma management, and trials now aim to achieve full remission rather than just symptom control.
Trials evaluate dupilumab combinations, tezepelumab (anti-TSLP) in Type 2 low asthma, itepekimab, biologic step-down strategies, and oral corticosteroid-sparing approaches. Digital inhalers with adherence monitoring are being validated as outcomes tools. Bronchial thermoplasty for severe non-biologic-responsive patients remains an active surgical comparator.
Frequently Asked Questions — eosinophilic asthma patients Clinical Trials
How many clinical trials are currently recruiting for eosinophilic asthma patients?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for eosinophilic asthma patients, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for eosinophilic asthma patients?
eosinophilic asthma patients research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a eosinophilic asthma patients clinical trial?
Eligibility criteria for eosinophilic asthma patients trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Guangdong Hengrui Pharmaceutical Co., Ltd 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology